Elevated soluble LOX-1 predicts risk of first-time myocardial infarction

References

• Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13(1):1. doi:10.1186/1475-2840-13-26.
   PubMedGoogle Scholar
• Ridker PM. How common is residual inflammatory risk? Circ Res. 2017;120(4):617–10. doi:10.1161/CIRCRESAHA.116.310527.
   PubMed Web of Science ®Google Scholar
• Nilsson J. Atherosclerotic plaque vulnerability in the statin era. Eur Heart J. 2017;38(21):1638–1644. doi:10.1093/eurheartj/ehx143.
   PubMed Web of Science ®Google Scholar
• Wong ND, Zhao Y, Quek RGW, et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis. J Clin Lipidol. 2017;11(5):1223–1233. doi:10.1016/j.jacl.2017.06.015.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-Dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi:10.1056/NEJMoa1912388.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, LoDoCo2 Trial I, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. doi:10.1056/NEJMoa2021372.
   PubMed Web of Science ®Google Scholar
• Pothineni NVK, Karathanasis SK, Ding Z, et al. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J Am Coll Cardiol. 2017;69(22):2759–2768. doi:10.1016/j.jacc.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Akhmedov A, Sawamura T, Chen CH, et al. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur Heart J. 2021;42(18):1797–1807. doi:10.1093/eurheartj/ehaa770.
   Web of Science ®Google Scholar
• Barreto J, Karathanasis SK, Remaley A, et al. Role of LOX-1 (lectin-like oxidized low-density lipoprotein receptor 1) as a cardiovascular risk predictor: mechanistic insight and potential clinical use. Arterioscler Thromb Vasc Biol. 2021;41(1):153–166. doi:10.1161/ATVBAHA.120.315421.
   PubMed Web of Science ®Google Scholar
• Akhmedov A, Rozenberg I, Paneni F, et al. Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. Eur Heart J. 2014;35(40):2839–2848. doi:10.1093/eurheartj/eht532.
   PubMed Web of Science ®Google Scholar
• Mehta JL, Sanada N, Hu CP, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100(11):1634–1642. doi:10.1161/CIRCRESAHA.107.149724.
   PubMed Web of Science ®Google Scholar
• Hu C, Dandapat A, Sun L, et al. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res. 2008;79(2):287–293. doi:10.1093/cvr/cvn110.
   PubMed Web of Science ®Google Scholar
• Partida RA, Libby P, Crea F, et al. Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. Eur Heart J. 2018;39(22):2070–2076. doi:10.1093/eurheartj/ehx786.
   PubMed Web of Science ®Google Scholar
• Markstad H, Edsfeldt A, Yao Mattison I, et al. High levels of soluble lectinlike oxidized low-density lipoprotein receptor-1 are associated with carotid plaque inflammation and increased risk of ischemic stroke. J Am Heart Assoc. 2019;8(4):e009874. doi:10.1161/JAHA.118.009874.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takano M, Hata N, et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnostic marker for rupture of thin-cap fibroatheroma: verification by optical coherence tomography. Int J Cardiol. 2013;168(4):3217–3223. doi:10.1016/j.ijcard.2013.04.110.
   PubMed Web of Science ®Google Scholar
• Balin M, Celik A, Kobat MA, et al. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI. J Thromb Thrombolysis. 2012;34(4):483–490. doi:10.1007/s11239-012-0770-2.
   PubMed Web of Science ®Google Scholar
• Inoue N, Okamura T, Kokubo Y, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem. 2010;56(4):550–558. doi:10.1373/clinchem.2009.140707.
   PubMed Web of Science ®Google Scholar
• Berglund G, Elmstähl S, Janzon L, et al. The malmo diet and cancer study. Design and feasibility. J Intern Med. 1993;233(1):45–51. doi:10.1111/j.1365-2796.1993.tb00647.x.
   PubMed Web of Science ®Google Scholar
• Hedblad B, Nilsson P, Janzon L, et al. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in malmo, Sweden. Diabet Med. 2000;17(4):299–307. doi:10.1046/j.1464-5491.2000.00280.x.
   PubMed Web of Science ®Google Scholar
• Rosvall M, Ostergren PO, Hedblad B, et al. Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the malmo diet and cancer study. Am J Epidemiol. 2000;152(4):334–346. doi:10.1093/aje/152.4.334.
   PubMed Web of Science ®Google Scholar
• Dichtl W, Stiko A, Eriksson P, et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19(12):3025–3032. doi:10.1161/01.atv.19.12.3025.
   PubMed Web of Science ®Google Scholar
• Persson M, Nilsson JA, Nelson JJ, et al. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007;190(2):388–396. doi:10.1016/j.atherosclerosis.2006.02.016.
   PubMed Web of Science ®Google Scholar
• Persson M, Hedblad B, Nelson JJ, et al. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27(6):1411–1416. doi:10.1161/ATVBAHA.107.142679.
   PubMed Web of Science ®Google Scholar
• Björkbacka H, Alm R, Persson M, et al. Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events. Arterioscler Thromb Vasc Biol. 2016;36(4):765–771. doi:10.1161/ATVBAHA.115.306938.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Sparse inverse covariance estimation with the graphical lasso. Biostatistics. 2008;9(3):432–441. doi:10.1093/biostatistics/kxm045.
   PubMed Web of Science ®Google Scholar
• Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: the story continues. Med Res Rev. 2020;40(1):79–134. doi:10.1002/med.21597.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–1308. doi:10.1126/science.281.5381.1305.
   PubMed Web of Science ®Google Scholar
• Mattisson IY, Björkbacka H, Wigren M, et al. Elevated markers of death receptor-Activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease. EBioMedicine. 2017;26:187–197. doi:10.1016/j.ebiom.2017.11.023.
   PubMed Web of Science ®Google Scholar
• Tummers B, Green DR. Caspase-8: regulating life and death. Immunol Rev. 2017;277(1):76–89. doi:10.1111/imr.12541.
   PubMed Web of Science ®Google Scholar
• Chen Y, Nilsson AH, Goncalves I, et al. Evidence for a protective role of placental growth factor in cardiovascular disease. Sci Transl Med. 2020;12(572):eabc8587. doi:10.1126/scitranslmed.abc8587.
   Web of Science ®Google Scholar
• Villa M, Cerda-Opazo P, Jimenez-Gallegos D, et al. Pro-fibrotic effect of oxidized LDL in cardiac myofibroblasts. Biochem Biophys Res Commun. 2020;524(3):696–701. doi:10.1016/j.bbrc.2020.01.156.
   PubMed Web of Science ®Google Scholar
• Yokoyama C, Aoyama T, Ido T, et al. Deletion of LOX-1 protects against heart failure induced by doxorubicin. PLoS One. 2016;11(5):e0154994. doi:10.1371/journal.pone.0154994.
   PubMed Web of Science ®Google Scholar
• Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications. 2001;15(4):203–210. doi:10.1016/s1056-8727(01)00143-x.
   PubMed Web of Science ®Google Scholar
• Nakhjavani M, Khalilzadeh O, Khajeali L, et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids. 2010;45(4):321–327. doi:10.1007/s11745-010-3401-8.
   PubMed Web of Science ®Google Scholar
• Femlak M, Gluba-Brzozka A, Cialkowska-Rysz A, et al. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16(1):207. doi:10.1186/s12944-017-0594-3.
   PubMedGoogle Scholar
• Srivastava RAK. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem. 2018;440(1-2):167–187. doi:10.1007/s11010-017-3165-z.
   PubMed Web of Science ®Google Scholar
• Lehrer-Graiwer J, Singh P, Abdelbaky A, et al. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015;8(4):493–494. doi:10.1016/j.jcmg.2014.06.021.
   PubMed Web of Science ®Google Scholar
• Mitsuoka H, Kume N, Hayashida K, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). Atherosclerosis. 2009;202(1):176–182. doi:10.1016/j.atherosclerosis.2008.04.002.
   PubMed Web of Science ®Google Scholar
• Hayashida K, Kume N, Murase T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation. 2005;112(6):812–818. doi:10.1161/CIRCULATIONAHA.104.468397.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RM, Pereira JPB, Nurmohamed NS, et al. Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. Eur Heart J. 2020;41(41):3998–4007. doi:10.1093/eurheartj/ehaa648.
   PubMed Web of Science ®Google Scholar
• Nurmohamed NS, Belo Pereira JP, Hoogeveen RM, et al. Targeted proteomics improves cardiovascular risk prediction in secondary prevention. Eur Heart J. 2022;43(16):1569–1577. doi:10.1093/eurheartj/ehac055.
   PubMed Web of Science ®Google Scholar